1188 related articles for article (PubMed ID: 26848160)
1. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063
[TBL] [Abstract][Full Text] [Related]
3. Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
Laitakari A; Ollonen T; Kietzmann T; Walkinshaw G; Mennerich D; Izzi V; Haapasaari KM; Myllyharju J; Serpi R; Dimova EY; Koivunen P
Redox Biol; 2019 Apr; 22():101145. PubMed ID: 30802717
[TBL] [Abstract][Full Text] [Related]
4. HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction.
Rahtu-Korpela L; Karsikas S; Hörkkö S; Blanco Sequeiros R; Lammentausta E; Mäkelä KA; Herzig KH; Walkinshaw G; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
Diabetes; 2014 Oct; 63(10):3324-33. PubMed ID: 24789921
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-Inducible Factor-1α Expression in Macrophages Promotes Development of Atherosclerosis.
Aarup A; Pedersen TX; Junker N; Christoffersen C; Bartels ED; Madsen M; Nielsen CH; Nielsen LB
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1782-90. PubMed ID: 27444197
[TBL] [Abstract][Full Text] [Related]
6. Genetic Ablation of Transmembrane Prolyl 4-Hydroxylase Reduces Atherosclerotic Plaques in Mice.
Määttä J; Serpi R; Hörkkö S; Izzi V; Myllyharju J; Dimova EY; Koivunen P
Arterioscler Thromb Vasc Biol; 2021 Jul; 41(7):2128-2140. PubMed ID: 34039020
[TBL] [Abstract][Full Text] [Related]
7. Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice.
Liu TT; Zeng Y; Tang K; Chen X; Zhang W; Xu XL
Atherosclerosis; 2017 Jul; 262():39-50. PubMed ID: 28500865
[TBL] [Abstract][Full Text] [Related]
8. Contribution of HIF-P4H isoenzyme inhibition to metabolism indicates major beneficial effects being conveyed by HIF-P4H-2 antagonism.
Tapio J; Halmetoja R; Dimova EY; Mäki JM; Laitala A; Walkinshaw G; Myllyharju J; Serpi R; Koivunen P
J Biol Chem; 2022 Aug; 298(8):102222. PubMed ID: 35787374
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis.
Meiler S; Baumer Y; Toulmin E; Seng K; Boisvert WA
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):323-31. PubMed ID: 25524771
[TBL] [Abstract][Full Text] [Related]
10. Deficiency of HIF1α in Antigen-Presenting Cells Aggravates Atherosclerosis and Type 1 T-Helper Cell Responses in Mice.
Chaudhari SM; Sluimer JC; Koch M; Theelen TL; Manthey HD; Busch M; Caballero-Franco C; Vogel F; Cochain C; Pelisek J; Daemen MJ; Lutz MB; Görlach A; Kissler S; Hermanns HM; Zernecke A
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2316-25. PubMed ID: 26404487
[TBL] [Abstract][Full Text] [Related]
11. HIF-P4H-2 deficiency protects against skeletal muscle ischemia-reperfusion injury.
Karsikas S; Myllymäki M; Heikkilä M; Sormunen R; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
J Mol Med (Berl); 2016 Mar; 94(3):301-10. PubMed ID: 26452676
[TBL] [Abstract][Full Text] [Related]
12. HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD.
Laitakari A; Tapio J; Mäkelä KA; Herzig KH; Dengler F; Gylling H; Walkinshaw G; Myllyharju J; Dimova EY; Serpi R; Koivunen P
J Mol Med (Berl); 2020 May; 98(5):719-731. PubMed ID: 32296880
[TBL] [Abstract][Full Text] [Related]
13. An unexpected intriguing effect of Toll-like receptor regulator RP105 (CD180) on atherosclerosis formation with alterations on B-cell activation.
Karper JC; de Jager SC; Ewing MM; de Vries MR; Bot I; van Santbrink PJ; Redeker A; Mallat Z; Binder CJ; Arens R; Jukema JW; Kuiper J; Quax PH
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2810-7. PubMed ID: 24115036
[TBL] [Abstract][Full Text] [Related]
14. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice.
Potì F; Gualtieri F; Sacchi S; Weißen-Plenz G; Varga G; Brodde M; Weber C; Simoni M; Nofer JR
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1505-12. PubMed ID: 23640484
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice.
Park KY; Heo TH
Cardiovasc Ther; 2018 Dec; 36(6):e12476. PubMed ID: 30378752
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.
van der Sluis RJ; Nahon JE; Reuwer AQ; Van Eck M; Hoekstra M
Br J Pharmacol; 2015 May; 172(9):2397-405. PubMed ID: 25572138
[TBL] [Abstract][Full Text] [Related]
17. SHP2 inhibitor PHPS1 protects against atherosclerosis by inhibiting smooth muscle cell proliferation.
Chen J; Cao Z; Guan J
BMC Cardiovasc Disord; 2018 Apr; 18(1):72. PubMed ID: 29703160
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte cathepsin C deficiency attenuates atherosclerotic lesion progression by selective tuning of innate and adaptive immune responses.
Herías V; Biessen EA; Beckers C; Delsing D; Liao M; Daemen MJ; Pham CC; Heeneman S
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):79-86. PubMed ID: 25395616
[TBL] [Abstract][Full Text] [Related]
19. ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages.
Laguna-Fernandez A; Checa A; Carracedo M; Artiach G; Petri MH; Baumgartner R; Forteza MJ; Jiang X; Andonova T; Walker ME; Dalli J; Arnardottir H; Gisterå A; Thul S; Wheelock CE; Paulsson-Berne G; Ketelhuth DFJ; Hansson GK; Bäck M
Circulation; 2018 Oct; 138(16):1693-1705. PubMed ID: 29739755
[TBL] [Abstract][Full Text] [Related]
20. Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice.
Myllymäki MNM; Määttä J; Dimova EY; Izzi V; Väisänen T; Myllyharju J; Koivunen P; Serpi R
Mol Cell Biol; 2017 Jan; 37(2):. PubMed ID: 27821476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
